New Daily HIV Pill Shows Promise in Replacing Complex Treatments

At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, a promising horizon emerged for people living with HIV. Pharmaceutical leaders Gilead Sciences and Merck presented late-stage clinical data demonstrating that new, highly effective daily single-tablet regimens can successfully keep the virus at bay.

Gilead unveiled detailed findings from its ARTISTRY-1 and ARTISTRY-2 trials, which tested a combination of bictegravir and the novel capsid inhibitor lenacapavir (BIC/LEN). The ARTISTRY-1 trial specifically targeted long-term survivors—with a median age of 60—who were managing their condition with complex regimens of between 2 and 11 pills a day. Remarkably, 96% of participants who switched to this single daily HIV pill maintained viral suppression after 48 weeks, proving non-inferior to the complex multi-tablet regimens. Beyond matching the efficacy of multi-tablet therapies, patients reported fewer lipid-related side effects, such as increased cholesterol, and experienced a significant boost in overall treatment satisfaction. Furthermore, the ARTISTRY-2 trial confirmed that the BIC/LEN combination was non-inferior to the current standard of care, Biktarvy, with only 1.3% of users having detectable HIV levels at 48 weeks.

Merck also brought compelling data to the conference, showcasing its own investigational daily tablet combining doravirine and islatravir (DOR/ISL). In its Phase 3 trials, Merck's drug also proved non-inferior to Biktarvy, achieving a 91.8% viral suppression rate at 48 weeks. The FDA is currently reviewing the DOR/ISL treatment, with a target action date set for April 28.

For the aging HIV population grappling with "pill fatigue," drug interactions, and drug resistance from decades of earlier treatments, these advancements are monumental. Streamlining care into a single daily HIV pill not only ensures durable virologic suppression but substantially improves the daily convenience and quality of life for long-term survivors.

---

🔖 Sources

Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens

Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data

---

Keywords: Daily HIV Pill

Daily HIV Pill

---